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Purpose: To describe the distribution of diagnostic procedures, rates of complications, and 
total cost of biopsies for patients with lung cancer.
Patients and Methods: Observational study using data from IBM Marketscan® Databases 
for continuously insured adult patients with a primary lung cancer diagnosis and treatment 
between July 2013 and June 2017. Costs of lung cancer diagnosis covered 6 months prior to 
index biopsy through treatment. Costs of chest CT scans, biopsy, and post-procedural 
complications were estimated from total payments. Costs of biopsies incidental to inpatient 
admissions were estimated by comparable outpatient biopsies.
Results: The database included 22,870 patients who had a total of 37,160 biopsies, of which 
16,009 (43.1%) were percutaneous, 14,997 (40.4%) bronchoscopic, 4072 (11.0%) surgical 
and 2082 (5.6%) mediastinoscopic. Multiple biopsies were performed on 41.9% of patients. 
The most common complications among patients receiving only one type of biopsy were 
pneumothorax (1304 patients, 8.4%), bleeding (744 patients, 4.8%) and intubation (400 
patients, 2.6%). However, most complications did not require interventions that would add 
to costs. Median total costs were highest for inpatient surgical biopsies ($29,988) and lowest 
for outpatient percutaneous biopsies ($1028). Repeat biopsies of the same type increased 
costs by 40–80%. Complications account for 13% of total costs.
Conclusion: Costs of biopsies to confirm lung cancer diagnosis vary substantially by type 
of biopsy and setting. Multiple biopsies, inpatient procedures and complications result in 
higher costs.
Keywords: cancer, diagnosis, economics, frequency
Introduction
Lung cancer is the leading cause of cancer-related deaths in both the United States 
and the world, causing more deaths than colorectal, breast, and prostate cancers 
combined. An estimated 154,050 Americans died of lung cancer in 2018, account-
ing for about 26% of all cancer deaths in the United States.1 The overall 5-year 
survival rate for patients with lung cancer is poor relative to the other major cancers 
(18.6%, vs 64.5% colorectal, 89.7% breast and 98.2% prostate). Survival rates vary 
from 53.6% for patients with localized disease, to 29.7% for patients with region-
ally invasive disease (local lymph nodal extension), and 4.7% for people with 
metastatic disease.2
Due to the lack of symptoms in the early stages of disease, most lung cancers 
(84%) are diagnosed late with the regional or distant extension of the disease, 
limiting treatment options and impacting survival.2 A variety of imaging technol-
ogies are used to identify suspicious lesions, but the discriminatory capability of 
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existing imaging technologies for diagnosis does not exist. 
Early detection of lung cancer offers the potential to mod-
ify the entire landscape of health services offered, perhaps 
at substantially lower costs to patients and health plans.
Tissue biopsy procedures play an essential role in the 
clinical pathway for the diagnosis of lung cancer. 
Guidelines, including those of the American College of 
Chest Physicians and National Comprehensive Cancer 
Network, are available to assess options that are best suited 
to different clinical scenarios.3,4 With the advent of new 
clinical assays to test for both germline and somatic altera-
tions that are prognostic and/or predictive of disease out-
come, toxicity or treatment, biopsy yield and specimen 
quality are critical to determine whether patients are candi-
dates for specific therapies.5 Inconclusive diagnostic proce-
dures increase the need for repeat biopsy, extend the time to 
treatment, add cost burden and undue psychological stress 
for patients and their families.
The objective of this paper is to describe the distribu-
tion of diagnostic procedures, rates of complications, and 
total cost of procedures related to lung cancer diagnosis 
using data from a US administrative claims database.
Patients and Methods
Database
This observational study utilized data from both the IBM 
Marketscan® Commercial Claims and Encounters and 
Medicare Supplemental Databases.6 The Marketscan® 
Databases are constructed from privately insured, paid, 
medical and prescription drug claims contributed by 
employers and health plans who have business relation-
ships with IBM Watson Health. Collectively, the data are 
incorporated from approximately 350 payers, including 
commercial insurance companies, Blue Cross and Blue 
Shield plans, and third-party administrators and include 
approximately 62 million covered lives. Each contributor’s 
database is constructed by collecting raw data from the 
participating payer(s). These raw data are service-level 
adjudicated paid claims and capitated encounters contain-
ing both inpatient and outpatient services. As the database 
is fully de-identified and compliant with HIPAA regula-
tions this study was exempted from Institutional Review 
Board approval.6
Study Population
The target population included patients aged 18 years and 
older who had one primary lung cancer diagnosis between 
July 1, 2013 and June 30, 2017 and had treatment after the 
diagnosis of lung cancer reported on medical claims. The 
diagnosis of lung cancer was based on the use of identified 
codes from the International Classification of Diseases, 
Ninth Revision (ICD-9-CM 162.x) and the International 
Classification of Diseases, Tenth Revision (ICD-10 C33, 
C34.xx) as both systems were used during the study per-
iod. Treatment was defined by identifying Current 
Procedural Terminology (CPT) and/or ICD-9-CM or 
ICD-10-CM procedure codes for surgery, ablation, radia-
tion therapy or chemotherapy, and the National Drug Code 
(NDC) for therapeutic agents used in the treatment of lung 
cancer in relation to a procedure. Patients without evi-
dence of health plan enrollment 6 months prior to and 
after their diagnosis and those who did not receive any 
lung cancer treatment after diagnosis were excluded from 
the focused study population (Figure 1).
Study Variables
We extracted the following information from the IBM 
MarketScan® database: date of diagnosis, type and number 
of procedures, cancer history, comorbidity, age, gender, 
and type of insurance plan. Comorbidity was calculated 
using Charlson comorbidity index score.7,8 Having only 
administrative data, other characteristics such as disease 
stage are unavailable. Procedures were stratified into four 
categories: CT-guided percutaneous biopsy, bronchoscopy, 
surgical biopsy, and mediastinoscopy. Chest CT scans 
were identified with CPT codes (71250, 71260, or 
71270). Biopsy-related complications captured were pneu-
mothorax, prolonged air leak, hemorrhage, post-treatment 
change to intubated/mechanical ventilation, mediastinitis, 
pneumonia, empyema and abscess of lung. ICD-9-CM or 
ICD-10-CM diagnosis codes were used to identify quali-
fying post-procedural complications (Supplement 
Information). Complications must have occurred within 
a day immediately following the biopsy procedure to be 
considered biopsy-related, except for prolonged air leak 
and abscess of the lung. For these complications, the time 
interval was 5 days after the biopsy date. To derive com-
plications and costs associated with each particular type of 
biopsy, we excluded patients who received more than one 
type of biopsy from the analysis. In addition, thoracotomy; 
with diagnostic wedge resection followed by anatomic 
lung resection (CPT code 32668) and thoracoscopy, surgi-
cal; with diagnostic wedge resection followed by anatomic 
lung resection (CPT code 32507) were excluded from the 
complications analysis, since we are unable to determine if 
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the complication was from the biopsy or a surgical 
treatment.
Cost Analysis
Total costs associated with a lung cancer diagnosis from 
the combined payer and patient perspectives beginning 6 
months prior to index date through treatment date were 
included in the analyses. Costs of chest CT scans, biopsy, 
and post-biopsy complications were estimated from total 
payments, as reported in the claims data. Costs for ser-
vices provided under capitated arrangements were esti-
mated using payment proxies that were computed based 
on average paid claims at the procedure level in the 
claims data. Costs of biopsy included both procedure 
and physician payment in the outpatient setting. Biopsy 
performed in the inpatient setting included all costs 
incurred to the payer during the entire hospital stay, 
including complication costs. Costs were normalized to 
2017 US dollars using the US Bureau of Labor 
Statistics’ Consumer Price Index Medical Care 
Component.
Costs associated with outpatient biopsies and inpatient 
biopsies where the biopsy occurs within the first 2 days of 
hospitalization are simply the reported payments. Biopsies 
that occur on the third day or later in a hospitalization are 
counted in this analysis, but the cost associated with the 
biopsy requires careful treatment. Attributing the entire 
payment for a hospitalization with what might be consid-
ered to be an incidental biopsy would overstate the true 
cost of the biopsy. Likewise, omitting any payment would 
understate the true cost. As a compromise, the costs of 
inpatient biopsies that occur after day 3 are estimated by 
Under the age of 18
N=37
Patient diagnosed before July 1, 
2013 or after June 30, 2017 
N=24,789
Health plan enrollment was not 
continuous six months before 
and after diagnosis 
N=20,602
Patients with primary lung cancer 
diagnosis and
treatment identified, 2013-2017 
N=73,732
Primary lung cancer diagnosis and 
treatment
July 1, 2013 and June 30, 2017
N=48,943
Continuous health plan enrollment six 
months before and after diagnosis
N=28,341
Age > 18 
N=28,304
Study Population
At least one biopsy procedure 
identified 
N=22,870





Multiple biopsy procedures of 
different types
N=7,303
Figure 1 Lung cancer patient characteristics by biopsy status.
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the average cost of the same type of biopsy occurring in an 
outpatient setting.
All analyses were conducted using the statistical soft-
ware SAS, version 9.4 (SAS Institute Inc.).
Results
A total of 73,732 patients with a primary diagnosis and 
evidence of treatment for lung cancer in their records 
between January 1, 2013 and December 31, 2017 were 
identified in the IBM MarketScan® database (Figure 1). Of 
these, 24,789 patients were diagnosed before July 1, 2013 
or after June 30, 2017 and were excluded from further 
analyses. An additional, 20,502 did not have evidence of 
continuous health insurance enrollment. Only 37 patients 
were ineligible due to age limits, leaving a total of 28,304 
patients for the final analytical sample. The study popula-
tion includes 81% of patients (N=22,870) with evidence of 
one or more biopsies in their claims data. Those patients 
with no evidence of biopsy (19.2%) tended to be younger 
than the overall population average, have higher Charlson 
comorbidity scores, have a history of cancer (both with 
and without evidence of metastasis), have no evidence of 
CT scans, and a greater percentage with the period from 
diagnosis to treatment exceeding 6 months (Table 1).
Fifty-eight percent of patients (N=13,270) underwent 
only one biopsy procedure of which 48.3% were percuta-
neous, 41.2% were bronchoscopic, 9.4% were surgical and 
1.1% were mediastinoscopy (Table 2). Another 27.7% 
required two, and the remaining 14.2% required three or 
more biopsy procedures. For the 41.9% of patients with 
more than one biopsy procedure of the same type, the 
overall percentage and distribution of procedures remained 
similar with slight increases in the frequency of surgical 
and mediastinoscopy procedures. Viewing these data by 
the type of procedure shows that 33.8% of patients had 
one or more percutaneous biopsies, 28.0% had one or 
more bronchoscopic biopsies, 5.5% had one or more sur-
gical biopsies and less than 1% had one or more medias-
tinoscopies. Approximately 32% had multiple biopsies of 
different types. (Supplemental Information)
In order to assess complication rates by biopsy type, 
we examined only patients receiving one or more biopsy 
procedures of the same type, resulting in a focused study 
population of 15,567 patients. Complication rates were 
highest among those patients receiving percutaneous 
biopsy, followed by bronchoscopy, mediastinoscopy and 
surgery (Table 3). Infection among patients undergoing 
surgical biopsy or mediastinoscopy was relatively rare. 
There were no cases of infection among those undergoing 
percutaneous or bronchoscopic biopsy procedures.
Median cost (and interquartile range) of single and multi-
ple biopsies, occurring in outpatient or inpatient settings, or 
both for some multiple biopsies are presented in Table 4. 
Median costs, including the biopsy, CT scan, and complica-
tions, were highest for inpatient surgical biopsies ($29,988) 
and lowest for outpatient percutaneous biopsies ($1028). 
Repeat biopsy procedures of the same type were most com-
mon in patients who had a percutaneous or bronchoscopic 
biopsy. Repeat biopsies of the same type increased costs by 
40–80%. The mean costs, irrespective of biopsy type, were 
$11,350, $23,651, $29,800, and $42,520 for one, two, three, 
or four or more biopsy procedures, respectively.
Median total costs varied substantially by setting. Over 
one-quarter (29%) of all biopsies were performed as inpa-
tient diagnostic procedures. Inpatient biopsies were cost-
lier than outpatient biopsies by a factor of 8 (single 
mediastinoscopy) to 20 (single surgical). Inpatient biopsies 
accounted for 81% of total costs.
Rates of complications varied substantially by type of 
procedures, though only a fraction of complications required 
further interventions that resulted in additional costs. 
Incremental costs associated with complications averaged 
$667, which corresponds to 13% of total costs. Complication 
costs were 11% of costs of patients receiving only one biopsy 
and 20% for patients receiving 2 or more biopsies.
Discussion
Nearly 42% of the study population underwent two or more 
biopsy procedures prior to the initiation of treatment, adding as 
much as 40–80% to the per patient median cost for percuta-
neous and bronchoscopic procedures. Bronchoscopic and per-
cutaneous biopsies accounted for approximately 90% of the 
procedures while surgery accounted for 10%, which is similar 
to the 11.4% reported by Vyas in 2013.9 Using the same 
Marketscan® database, Zhang et al analyzed the frequency of 
biopsy procedures in a lung cancer patient population for 
2013–15,10 and Shinde et al analyzed the frequency of biopsy 
procedures in a lung cancer patient population using erlotinib 
or crizotinib for 2009–2012.11 Zhang et al used the same 
continuous enrollment criteria of 6 months prior to and 6 
months following biopsy and did not examine costs. Shinde 
et al selected patients based on an index claim for the use of 
either erlotinib or crizotinib, and continuous enrollment 12 
months prior to and 12 months following biopsy. Even with 
these differences, our findings in terms of the number of 
additional procedures are quite similar to both studies.
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Table 1 Lung Cancer Patient Characteristics by Biopsy Status
Variable No Biopsy Received Biopsies P value
N % n % n %
Total 28,304 100.0 5434 19.2 22,870 80.8
Age at diagnosis <0.001
18–44 866 3.1 226 4.2 640 2.8
45–54 3442 12.2 845 15.6 2597 11.4
55–64 10,234 36.2 2016 37.1 8218 35.9
65–74 7375 26.1 1291 23.8 6084 26.6
75–84 5287 18.7 828 15.2 4459 19.5
85+ 1100 3.9 228 4.2 872 3.8
Gender <0.01
Male 13,750 48.6 2553 47.0 11,197 49.0
Female 14,554 51.4 2881 53.0 11,673 51.0
Type of insurance 0.0945
EPO 225 0.8 39 0.7 186 0.8
HMO 2573 9.1 521 9.6 2052 9.0
POS 1836 6.5 354 6.5 1482 6.5
PPO 14,386 50.8 2816 51.8 11,570 50.6
Other 9284 32.8 1704 31.4 7580 33.1
Year of diagnosis <0.001
2013 5518 19.5 1146 21.1 4372 19.1
2014 8444 29.8 1680 30.9 6764 29.6
2015 6568 23.2 1209 22.3 5359 23.4
2016 5430 19.2 1003 18.5 4427 19.4
2017 2344 8.3 396 7.3 1948 8.5
Charlson comorbidities index* <0.001
0 6056 21.4 1033 19.0 5023 22.0
1 6629 23.4 817 15.0 5812 25.4
2+ 15,619 55.2 3584 66.0 12,035 52.6
Cancer history* <0.001
No 20,597 72.8 3105 57.1 17,492 76.5
Yes (No metastatic record) 5883 20.8 1594 29.3 4289 18.8
Yes (Metastasis to other organs) 998 3.5 475 8.7 523 2.3
Yes (Metastasis to lung) 826 2.9 260 4.8 566 2.5
Total CT scans* <0.001
0 6878 24.3 2047 37.7 4831 21.1
1 18,442 65.2 2903 53.4 15,539 67.9
2 2615 9.2 402 7.4 2213 9.7
3+ 369 1.3 82 1.5 287 1.3
Time from diagnosis to treatment <0.001
Same day 2531 8.9 608 11.2 1923 8.4
Within 6 months 23,811 84.1 4160 76.6 19,651 85.9
More than 6 months 1962 6.9 666 12.3 1296 5.7
Notes: Others include comprehensive, Medicare wrap-around, consumer driven, and high deductible health plans, and missing values. Asterisk*Clinical characteristics were 
identified up to 6 months prior to lung cancer diagnosis. 
Abbreviations: Type of insurance: EPO, exclusive provider organization; HMO, health maintenance organization; POS, point of service; PPO, preferred provider 
organization.
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Complication rates following biopsy procedures likely 
depend upon a variety of factors including patient char-
acteristics (eg, comorbidities, location of lesions), proce-
dural processes (eg, puncture time length), the length of 
time following the procedure to assess a complication and 
the type of study (eg, case series vs clinical trial). In the 
recent literature, pneumothorax with transthoracic needle 
aspiration remains the most frequently reported complica-
tion, with rates ranging from 15% to 25%, of which 
6–11% of those patients requiring a chest tube for 
management.12,13 A recent meta-analysis by Heerink 
et al reported a pooled pneumothorax complication rate 
of 25.3% and 18.8% for a core biopsy and fine-needle 
aspiration, respectively. However, pneumothorax compli-
cation rates varied widely from 8.4% to 53.5%. The 
pooled estimate for bleeding complications was 18% and 
6.4% for a core biopsy and fine-needle aspiration, respec-
tively. Bleeding complication rates showed even more 
variability ranging from 2.9% to 54.4%.14 In our study, 
the complication rates for pneumothorax and hemorrhage 
following percutaneous biopsy were 14.64% and 2.2%, 
respectively. One possible explanation for the lower rates 
observed in our study is the exclusion of 7303 patients 
who received multiple biopsy procedures of different 
approaches. The inclusion of this subset into complication 
rate estimates is a subject for further study.
To ensure that we accurately achieve the objective of 
our study to evaluate the total costs, we included specific 
procedure codes and limited the window of observation to 
ensure that our study complication rates were similar to 
other published findings; thus validating complication 
rates and ensuring that interventions to patient clinical 
pathways which would impact costs. As such, the compli-
cation rate associated with bronchoscopic procedures is 
considerably lower than the complication rate associated 
with percutaneous procedures. In a meta-analysis of 
guided bronchoscopy for the evaluation of the pulmonary 
nodule, Memoli et al reported a pneumothorax rate of 
approximately 1.5% and no events of bleeding.15 In 
a multi-center study of consecutive patients undergoing 
bronchoscopy, rates of pneumothorax and hemorrhage 
were 1.7% and 0.1%, respectively.16 Our results show 
comparable findings for pneumothorax but higher rates 
for hemorrhage or bleeding given the varying degree of 
hemorrhage and the subsequent need for blood 
transfusion.17 While our study finds a higher rate of 
hemorrhage, we also find that these patients did not require 
an intervention of transfusion; indicating that these bleed 
types were of minor complexity and resolved on their own. 
Furthermore, published complication rates for surgical 
biopsy are approximately 5%, inclusive of air leaks and 
pneumonia.3 In our study, approximately 2% of patients 
undergoing surgical biopsy experienced air leaks and 
pneumonia, lower, but comparable to previously published 
findings.
Lung cancer has been estimated to cost approximately 
$60,000 in the first year after diagnosis and approximately 
$8000 per year thereafter. Costs during the last year of life 
may exceed $90,000.18,19 There is little information on the 
costs of lung cancer from nodule biopsy to cancer therapy. In 
this study, repeat biopsies increased costs by 40–80%. 
Lokhandwala and colleagues estimated the total diagnostic 
cost for patients from an abnormal chest CT scan to assess-
ment for lung cancer diagnosis using Medicare data and 
reported a combined value of $38.3 million in their final 
sample, of which 43.1% was accounted for by patients 
receiving biopsy procedures without lung cancer.20
Huo et al estimated complication costs following 
biopsy procedures and reported mean incremental costs 
of $6320 for minor complications to $56,845 for major 
complications.21 However, their analysis included costs 
for complications for one full year, rather than an episo-
dic analysis of 1 day to 5 days post procedure, and also 
included surgical treatment within the surgical biopsy 
Table 2 Distribution of Biopsies by Frequency
Patients Percutaneous Bronchoscopy Surgical Mediastinoscopy
Biopsy Procedures n % n % n % n % n %
1 procedure 13,270 58.0 6410 48.3 5468 41.2 1244 9.4 148 1.1
2 procedures 6342 27.7 5124 40.4 5264 41.5 1601 12.6 695 5.5
3 procedures 2266 9.9 2641 38.9 2629 38.7 798 11.7 730 10.7
≥ 4 procedures 992 4.3 1834 41.6 1636 37.1 429 9.7 509 11.6
Overall 22,870 100.0 16,009 43.1 14,997 40.4 4072 11.0 2082 5.6
Note: Average procedures per patient: 1.6 (37,160 biopsies divided by 22,870 patients).
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definition. Our finding of average complication costs was 
$667, 13% of the overall median costs, suggesting lower 
cost associated with complications. Multiple biopsies 
create additional costs due to the procedure itself, as 
well as additional costs associated with complications 
associated with the second, third or fourth biopsy. We 
attribute all of the costs of complications to the compli-
cation directly. A case could be made for attributing 
some of the costs of complications to having multiple 
biopsies, making the 13% value an overestimate.
Our analysis suggests that the key drivers of the costs 
of biopsies are repeat procedures and the procedure set-
ting. The lower impact of complication costs in this study 
may also be attributable to the exclusion of patients with 
multiple biopsy types, though some portion of complica-
tion costs may be attributable to the process of multiple 
biopsies. Additionally, patients were only counted once for 
the rates of different types of complication even though 
there may have been multiple reports of the same type of 
complication. Complications were rarely associated with 
treatment, identified by a unique procedure code within the 
timing conditions of this study. The impact of episodic 
MS-DRG bundling on the costs of complications is 
unknown.
Limitations
As with any data source, IBM MarketScan® has limita-
tions. Claims data come mostly from large employers 
providing coverage for their employees and dependents. 
The study population does not include persons who are 
uninsured, publically insured other than by Medicare, or 
persons without continuous enrollment. Unique to the US, 
nearly 30% of those diagnosed with lung cancer in these 
data did not have evidence of continuous health insurance 
enrollment, which is typically associated with a person’s 
changing employment status or employer’s changing 
insurance. The study likely disproportionately excludes 
persons who have low incomes. Thus, the results may 
not be generalizable to the US population as a whole, 
nor to other jurisdictions where the entire population is 
insured.
Claims data are focused on administrative rather than 
clinical information. Clinical information that may be very 
relevant in analyses of complications and costs, such as the 
stage of disease upon diagnosis, are not included in claims 
data. For this discussion of lung cancer, the absence of 







































































































































































































































































































































































































































































ClinicoEconomics and Outcomes Research 2021:13                                                                    submit your manuscript | www.dovepress.com                                                                                                                                                                                                                       
DovePress                                                                                                                         
197
Dovepress                                                                                                                                                             Chiu et al
A large number of patients, 5434 (19.2%), were 
observed to have lung cancer therapy with no evidence 
of biopsy. Zhang et al found an even higher percentage of 
patients (45.7%) with a lack of identifiable biopsy within 6 
months of diagnosis.10 Some patients, with a history of 
cancer or a first observed diagnosis on claims beyond 6 
months, may have merely experienced delayed treatment. 
However, it is a mystery how the diagnosis of cancer was 
made for these patients and reflects a limitation of the data. 
We can provide no estimate of the costs of a lung cancer 
diagnosis for these patients. Further, using a 6-month time 
period may have limited observing some costs associated 
with a protracted diagnosis process.
We used a single diagnosis of lung cancer in the 
primary diagnosis position as evidence of lung cancer. 
By using only claims data, we did not have a confirmed 
pathological diagnosis of cancer. A single diagnosis may 
not be a severe limitation. Ramsey et al evaluated the 
sensitivity of a single medical claim with a lung cancer 
diagnosis, which was confirmed with the SEER registry, 
and reported a sensitivity of 99.4% for commercial plan 
members.22
Claims were counted until the point of treatment. 
While we attempted to separate diagnosis and treatment 
claims, we may have included some costs associated with 
treatments if claims for diagnosis and treatments were 
combined. This is particularly a concern for patients with 
inpatient admissions. The costs presented for inpatient 
biopsies may be biased upwards from true costs.
This analysis also excluded patients who received mul-
tiple biopsy types, a population subset that may have more 
complications, limiting the scope of the analysis. With 
multiple biopsy types, we were unable to attribute costs 
and complications to a specific biopsy. We also limited the 
inclusion of complications to those occurring within a time 
window of 1 day to 3 days after the procedure. Analysis of 
complication rates and costs associated with multiple 
biopsy types in this population, longer time windows for 
observing complications, as well as analyses of the asso-
ciations among patients’ demographic characteristics, 
complications and costs, are subjects for further research.
Conclusion
Healthcare costs associated with the diagnosis of lung cancer 
are primarily driven by repeat procedures and setting (inpa-
tient versus outpatient). In our analysis, 41.9% of diagnosed 
and treated lung cancer patients undergo multiple biopsies, 
increasing mean healthcare costs by 40–80% depending on 
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Notes: Asterisk*: selected inpatient and combination. Both outpatient and inpatient include biopsies that occurred outside of the range of hospital day −1 to +2, where 
costs were estimated to be the median cost of outpatient biopsies of the same type.
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procedure type. Multiple biopsies add substantially to the cost 
burden of lung cancer diagnosis, leaving an opportunity for 
technological advancements that increase accuracy and effec-
tiveness, leading to fewer repeat biopsies. Over one-quarter of 
procedures were performed on an inpatient basis, leaving an 
opportunity for greater use of outpatient services, when medi-
cally appropriate, to substantially reduce payer costs.
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